News By Tag
News By Place
EpiCast Report: Breast Cancer - Epidemiology Forecast to 2022
Breast Cancer: Incident and Prevalent Cases Continue to Grow as Effective Screening Boosts Survival Rates
The company’s latest report* states that the number of five-year prevalent cases will also grow by 44%, climbing from 3.7 million in 2012 to 5.39 million by 2022. Out of the 9MM, the US and urban China had the highest number of five-year prevalent cases in 2012, with 1.15 million and 898,406 cases, respectively.
Samantha Lee, GlobalData’s Epidemiologist, says: “The forecast growth in breast cancer incidence is partly due to rising cases of obesity, growing detection through screening programs, and changes in reproductive patterns and the use of postmenopausal hormone replacement therapy.”
According to the World Health Organization, increased breast cancer survival has contributed greatly to the prevalence of the disease, and there is a large amount of evidence showing that breast cancer mammographic screening is effective in reducing the disease mortality by at least 20% in women aged 50 years and older.
For Sample Pages, please click or add the below link to your browser:
Lee says: “Prevention measures taken to improve breast cancer survival in parts of the world where organized nationwide mammography screening has only been made available in recent years, such as Brazil and China, will boost survival rates and impact the disease incidence and prevalence in those countries.”
Nonetheless, GlobalData epidemiologists expect the impact of screening in these markets to be limited in the short term. This is due to the lack of sufficient resources and infrastructure needed to support the downstream healthcare needs associated with screening, such as additional diagnostic tests and treatment.
This report provides an overview of the risk factors and global trends of invasive breast cancer in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and urban China). It includes a 10-year epidemiological forecast for the incident cases, and five-year prevalent cases, of breast cancer in women segmented by age, natural menopausal status, cancer stage at diagnosis, and hormone receptor subtypes. This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
GlobalData is the premier source of actionable insight into the energy and healthcare industries. With the combined expertise of more than 1,000 researchers, market analysts and consultants, we provide high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.globaldata.com/
For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782